SEC Form 4 · accession 0001587221-18-000008
Zosano Pharma Corp · ZSAN
Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗
Reporting owner
Kenneth Greathouse
Director
Period of report
Jan 2, 2018
Accepted (ET)
Mar 2, 2018 · 7:22 pm EST
Rule 10b5-1 plan
unknown — predates the checkbox
Issuer CIK
0001587221
Table I — non-derivative securities
No Table I lines on this filing.
Table II — derivative securities
| Security | Conv. / exercise price | Date | Code | Shares | A/D | Exercisable | Expires | Underlying | Underlying shares | Owned after | D/I |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Stock Option (right to buy)F2,F1,F3 | $0.53 | Jan 2, 2018 | A | 30,000 | A | — | Jan 2, 2028 | Common Stock | 30,000 | 30,000 | D |
Explanation of responses
- F1As a result of a 1-for-20 reverse stock split of the common stock of the Company, which became effective at 5:00 p.m. Eastern Time on January 25, 2018 (the "Reverse Split"), the exercise price has increased from $0.53 per share to $10.60 per share.
- F2As a result of the Reverse Split, the number of shares of the Company's common stock underlying the stock option has decreased from 30,000 shares to 1,500 shares.
- F3The shares underlying the option shall vest on the first anniversary of the date of grant.